CATETERI PER EMBOLECTOMIA DOPPIO LUME

Informazioni principali

  • Nome commerciale:
  • CATETERI PER EMBOLECTOMIA DOPPIO LUME
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Dispositivo medico

Documenti

  • per il pubblico:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per il pubblico.

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • CATETERI PER EMBOLECTOMIA DOPPIO LUME
    Italia
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Gruppo terapeutico:
  • CATETERI PER EMBOLECTOMIA

Altre informazioni

Status

  • Fonte:
  • Ministero della Salute - Italia
  • Stato dell'autorizzazione:
  • S
  • Data dell'autorizzazione:
  • 23-06-2010
  • Ultimo aggiornamento:
  • 09-08-2016
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.

    Richiedi il foglio illustrativo per il pubblico.

18-12-2018

Medicines Safety Update, Volume 9, Number 4, December 2018

Medicines Safety Update, Volume 9, Number 4, December 2018

Infliximab and mycosis fungoides, infliximab and lupus-like syndrome, and medicine shortages mandatory reporting

Therapeutic Goods Administration - Australia

9-11-2018

Medical Devices Safety Update, Volume 6, Number 6, November 2018

Medical Devices Safety Update, Volume 6, Number 6, November 2018

Standards minimise risk of misconnections; eltrombopag interference with test results; amniotic fluid tests

Therapeutic Goods Administration - Australia

26-9-2018

Medical Devices Safety Update, Volume 6, Number 5, September 2018

Medical Devices Safety Update, Volume 6, Number 5, September 2018

Case studies in Incident Report Investigations; review of reusable biopsy forceps devices; care required with patient lifters

Therapeutic Goods Administration - Australia

27-7-2018

Pending EC decision:  Ilumetri, tildrakizumab, Opinion date: 26-Jul-2018

Pending EC decision: Ilumetri, tildrakizumab, Opinion date: 26-Jul-2018

Europe - EMA - European Medicines Agency

26-7-2018

Medical Devices Safety Update Volume 6, Number 4, July 2018

Medical Devices Safety Update Volume 6, Number 4, July 2018

Be aware of cross-reactivity with home-use self-test ovulation kits, TGA undertakes product safety review into intragastric balloon systems

Therapeutic Goods Administration - Australia

29-6-2018

Medicines Safety Update, Volume 9, Number 2, June 2018

Medicines Safety Update, Volume 9, Number 2, June 2018

Oral methotrexate dosing, medicines associated with a risk of neuropsychiatric adverse events, and clozapine and gastrointestinal effects

Therapeutic Goods Administration - Australia

6-6-2018

Opinion/decision on a Paediatric investigation plan (PIP):    -, Selumetinib, Therapeutic area: Oncology

Opinion/decision on a Paediatric investigation plan (PIP): -, Selumetinib, Therapeutic area: Oncology

Europe - EFSA - European Food Safety Authority EFSA Journal

25-5-2018

Medical Devices Safety Update Volume 6, Number 3, May 2018

Medical Devices Safety Update Volume 6, Number 3, May 2018

How TGA uses joint replacement registry data; Focus on skills for vacuum-assisted births; TGA reviews product safety of ventilators

Therapeutic Goods Administration - Australia

20-3-2018

Medicines Safety Update, Volume 9, Number 1, February-March 2018

Medicines Safety Update, Volume 9, Number 1, February-March 2018

First-generation oral sedating antihistamines – use in children, Suvorexant (Belsomra) – next day effects, Desvenlafaxine (Pristiq) recommended dose, Miconazole and potential interaction with warfarin

Therapeutic Goods Administration - Australia

18-3-2018

Medical Devices Safety Update Volume 6, Number 2, March 2018

Medical Devices Safety Update Volume 6, Number 2, March 2018

Preventable alarm issues; Review into cochlear implants; NHS cylinder alert; recent safety alerts

Therapeutic Goods Administration - Australia

19-9-2018

Ilumetri (Almirall, S.A.)

Ilumetri (Almirall, S.A.)

Ilumetri (Active substance: tildrakizumab) - Centralised - Authorisation - Commission Decision (2018)6106 of Wed, 19 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4514

Europe -DG Health and Food Safety

2-8-2018

EU/3/18/2050 (AstraZeneca AB)

EU/3/18/2050 (AstraZeneca AB)

EU/3/18/2050 (Active substance: Selumetinib) - Orphan designation - Commission Decision (2018)5282 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/045/18

Europe -DG Health and Food Safety

28-5-2018

Seresto and its associated name Foresto

Seresto and its associated name Foresto

Seresto and its associated name Foresto (Active substance: imidacloprid/flumethrin) - Community Referrals - Art 13 - Commission Decision (2018)3404 of Mon, 28 May 2018 European Medicines Agency (EMA) procedure number: EMEA/V/A/125

Europe -DG Health and Food Safety